Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
6.31
0.00 (0.00%)
At close: Oct 5, 2026, 4:00 PM EDT
6.50
+0.19 (3.01%)
Pre-market: Oct 6, 2026, 7:07 AM EDT
Precision BioSciences Revenue
Precision BioSciences had revenue of $45.06M in the twelve months ending June 30, 2026, up 3,472.96% year-over-year. In the year 2025, Precision BioSciences had annual revenue of $34.26M, down -50.12%.
Revenue (ttm)
$45.06M
Revenue Growth
+3,472.96%
P/S Ratio
3.87
Revenue / Employee
$672,463
Employees
67
Market Cap
174.17M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 34.26M | -34.43M | -50.12% |
| Dec 31, 2024 | 68.70M | 19.97M | 40.98% |
| Dec 31, 2023 | 48.73M | 23.63M | 94.15% |
| Dec 31, 2022 | 25.10M | -90.43M | -78.28% |
| Dec 31, 2021 | 115.53M | 91.24M | 375.72% |
| Dec 31, 2020 | 24.29M | 2.05M | 9.20% |
| Dec 31, 2019 | 22.24M | 11.36M | 104.34% |
| Dec 31, 2018 | 10.88M | 4.40M | 67.84% |
| Dec 31, 2017 | 6.48M | -531.00K | -7.57% |
| Dec 31, 2016 | 7.02M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 50.94M |
| Cue Biopharma | 37.66M |
| MediWound | 11.86M |
| Oramed Pharmaceuticals | 2.00M |
| Veraxa Biotech AG | 29.54K |
DTIL News
- 19 days ago - Precision BioSciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 6 weeks ago - BioSciences doses first patient in Phase 1/2 FUNCTION-DMD clinical trial - TheFly
- 6 weeks ago - Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study - Business Wire
- 6 weeks ago - Precision BioSciences to present data from OTC-HOPE trial of ECUR-506 - TheFly
- 2 months ago - Precision BioSciences Earnings release: Q2 2026 - Filings
- 2 months ago - Precision BioSciences Quarterly report: Q2 2026 - Filings
- 2 months ago - Precision BioSciences reports Q2 EPS ($1.26) vs. ($2.13) last year - TheFly
- 2 months ago - Precision BioSciences sees cash runway through 2028 - TheFly